FrancophonIA/ELRC3.0 huggingface dataset:
English: • have a severe allergic rhinitis (allergy affecting the nose and airways);
Estonian: • raske allergiline riniit (nina ja hingamisteede allergia);
English: Why has Azarga been approved?
Estonian: Miks Azarga heaks kiideti?
English: Azarga is a medicine that contains two active substances, brinzolamide and timolol.
Estonian: Azarga on ravim, mis sisaldab kaht toimeainet, brinsolamiidi ja timolooli.
English: The second was a 12-month study comparing Azarga with the combination of timolol and dorzolamide (another carbonic anhydrase inhibitor) in 437 patients.
Estonian: Teine uuring (437 patsienti) kestis 12 kuud ja selles võrreldi Azargat timolooli ja dorsolamiidi (samuti karboanhüdraasi inhibiitor) kombinatsiooniga.
English: • have severe chronic obstructive pulmonary disease (COPD, a disease causing narrowing of the airways);
Estonian: • raske krooniline obstruktiivne kopsuhaigus (hingamisteede ahenemist põhjustav haigus);
English: Azarga contains benzalkonium chloride, which is known to discolour soft contact lenses.
Estonian: Azarga sisaldab bensalkooniumkloriidi, mis muudab pehmete kontaktläätsede värvust.
English: Azarga contains two active substances, brinzolamide and timolol.
Estonian: Azarga sisaldab kahte toimeainet, brinsolamiidi ja timolooli.
English: In the second study, IOP had fallen from around 26 mmHg by around 8.3 mmHg after six months in both groups of patients.
Estonian: Teises uuringus oli silma siserõhk 6 kuu pärast vähenenud mõlemas patsiendirühmas esialgselt väärtuselt (ligikaudu 26 mm Hg) ligikaudu 8,3 mm Hg võrra.
English: Bicarbonate is required for the production of the aqueous humour.
Estonian: Bikarbonaatioone on vaja silma vesivedeliku tekkimisel.
English: • have severely reduced kidney function.
Estonian: • neerutalitluse raske häire.
English: It must not be used by patients who:
Estonian: Azargat ei tohi kasutada järgmiste seisunditega patsiendid:
English: In the first study, IOP fell from around 21 mmHg by 8.0 to 8.7 mmHg in the patients using Azarga.
Estonian: Esimeses uuringus vähenes silma siserõhk Azargat saanud patsientidel esialgselt väärtuselt (ligikaudu 21 mm Hg) 8,0-8,7 mm Hg võrra.
English: Azarga is used to reduce intra-ocular pressure (IOP, pressure inside the eye).
Estonian: Azargat kasutatakse silma siserõhu alandamiseks.
English: How has Azarga been studied?
Estonian: Kuidas Azargat uuriti?
English: What benefit has Azarga shown during the studies?
Estonian: Milles seisneb uuringute põhjal Azarga kasulikkus?
English: How is Azarga used?
Estonian: Kuidas Azargat kasutatakse?
English: What is Azarga used for?
Estonian: Milleks Azargat kasutatakse?
English: The first was a six-month study comparing Azarga with brinzolamide and with timolol used on their own in 523 patients.
Estonian: Esimene uuring (523 patsienti) kestis 6 kuud ja selles võrreldi Azargat brinsolamiidi ja timolooliga kasutamisel ainsa ravimina.
English: How does Azarga work?
Estonian: Kuidas Azarga toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Azarga on retseptiravim.
English: This summary was last updated in 12-2008.
Estonian: Kokkuvõtte viimane uuendus: 12-2008.
English: The full list of these medicines is available in the Package Leaflet.
Estonian: Nende ravimite täielik loetelu on pakendi infolehel.
English: The European Commission granted a marketing authorisation valid throughout the EU for Insulin Human Winthrop to Sanofi-Aventis Deutschland GmbH on 17 January 2007.
Estonian: Euroopa Komisjon andis Insulin Human Winthropi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Sanofi-Aventis Deutschland GmbH 17. jaanuaril 2007.
English: The studies also looked at the number of patients who developed hypoglycaemia (low blood glucose levels).
Estonian: Uuringutes vaadeldi ka nende patsientide arvu, kellel tekkis hüpoglükeemia (vere väike glükoosisisaldus).
English: It is supplied in vials, cartridges, or pre-filled disposable pens (OptiSet and SoloStar).
Estonian: Seda turustatakse viaalide, ampullide ja eeltäidetud ühekordsete pensüstaldena (OptiSet ja SoloStar).
English: Insulin Human Winthrop Rapid may also be given into a vein, but only in hospital where the patient can be closely monitored.
Estonian: Insulin Human Winthrop Rapidit võib manustada ka veeni, kuid ainult haiglas, kus patsienti on võimalik pidevalt jälgida.
English: The studies measured the ‘fasting' blood glucose levels (measured when the patient had not eaten for at least eight hours), or the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
Estonian: Uuringutel mõõdeti vere glükoosisisaldust tühja kõhuga (kui patsient ei olnud söönud vähemalt kaheksa tundi) või teatud aine - glükosüleeritud hemoglobiini (HbA1c)sisaldust veres, mis näitab, kui hästi reguleerib organism vere glükoosisisaldust.
English: This medicine is the same as Insuman, which is already authorised in the European Union (EU).
Estonian: See ravim on identne Insumaniga, millele on Euroopa Liidus müügiluba juba antud.
English: • Insulin Human Winthrop Comb 50: 50% soluble insulin and 50% crystalline protamine insulin.
Estonian: • Insulin Human Winthrop Comb 50: 50% lahustuvat insuliini ja 50% kristalset protamiininsuliini.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) INSULIN HUMAN WINTHROP RAPID INSULIN HUMAN WINTHROP BASAL INSULIN HUMAN WINTHROP COMB (15, 25, 30, 50) INSULIN HUMAN WINTHROP INFUSAT EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE INSULIN HUMAN WINTHROP RAPID INSULIN HUMAN WINTHROP BASAL INSULIN HUMAN WINTHROP COMB (15, 30, 25, 50) INSULIN HUMAN WINTHROP INFUSAT Kokkuvõte üldsusele
English: Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose.
Estonian: Suhkurtõbi on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini.
English: By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
Estonian: Vere glükoosisisalduse reguleerimisega vähenevad suhkurtõve sümptomid ja tüsistused.
English: The company that makes Insuman has agreed that its scientific data can be used for Insulin Human Winthrop.
Estonian: Insumani tootev ettevõte on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Insulin Human Winthropi korral.
English: The desired blood glucose levels, the type of Insulin Human Winthrop to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient's diet, physical activity and lifestyle.
Estonian: Vajaliku glükoosisisalduse veres, kasutatava Insulin Human Winthropi liigi, annuse ja süste ajastamise määrab kindlaks arst iga patsiendi puhul eraldi ning kohandab neid vastavalt patsiendi dieedile, kehalisele aktiivsusele ja elustiilile.
English: Insulin Human Winthrop has been studied in two trials in 611 patients with either type 1 diabetes (when the body cannot produce insulin) or type 2 diabetes (when the body is unable to use insulin effectively).
Estonian: Insulin Human Winthropiga korraldati kaks uuringut, milles osales kokku 611 patsienti, kes olid kas I tüüpi suhkurtõvega patsiendid (kelle kõhunäärmes ei teki insuliini) või II tüüpi suhkurtõvega patsiendid (kelle organism ei suuda insuliini tõhusalt kasutada).
English: Insulin Human Winthrop Rapid can also be used for the treatment of hyperglycaemic coma (coma caused by too much blood glucose [sugar]) and ketoacidosis (high levels of ketones [acids] in the blood), and to control blood glucose before, during or after an operation.
Estonian: Insulin Human Winthrop Rapidit võib kasutada ka hüperglükeemilise kooma (kooma, mille põhjuseks on vere liiga suur glükoosisisaldus [suhkrusisaldus]) ja ketoatsidoosi (ketoonide ja hapete suur sisaldus veres) raviks ning vere glükoosisisalduse reguleerimiseks enne operatsiooni, selle ajal ja pärast seda.
English: The patient's blood glucose should be tested regularly to find the lowest effective dose.
Estonian: Vähima tõhusa annuse leidmiseks peab korrapäraselt määrama patsiendi vere glükoosisisaldust.
English: Insulin Human Winthrop contains insulin in various forms: the soluble form, which acts quickly (within 30 minutes of injection), and the isophane and crystallineprotamine forms, which are absorbed much more slowly during the day, giving them a longer duration of action.
Estonian: Insulin Human Winthrop sisaldab insuliini mitmesugusel kujul: lahustuvat insuliini, mis toimib kiiresti (30 minuti jooksul pärast süstimist), ning isofaaninsuliini ja kristalset protamiininsuliini, mis imenduvad ööpäeva jooksul palju aeglasemalt ja pikendavad seega toimeaega.
English: Insulin Human Winthrop should be given before meals.
Estonian: Insulin Human Winthropit peab süstima enne sööki.
English: The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Asendusinsuliin toimib samuti kui loomulikul teel tekkiv insuliin, aidates glükoosil siseneda verest rakkudesse.
English: Insulin Human Winthrop should not be used in people who may be hypersensitive (allergic) to insulin human or any of the other ingredients.
Estonian: Insulin Human Winthropit ei tohi kasutada patsiendid, kes võivad olla iniminsuliini või ravimi mis tahes muu koostisosa suhtes ülitundlikud (allergilised).
English: Insulin Human Winthrop doses might need to be adjusted when it is given with other medicines that may have an effect on blood glucose levels.
Estonian: Insulin Human Winthropi annuseid võib vajaduse korral kohandada, kui seda kasutatakse koos muu ravimiga, mis võib mõjutada vere glükoosisisaldust.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Insulin Human Winthrop's benefits are greater than its risks for the treatment of diabetes mellitus.
Estonian: Inimravimite komitee otsustas, et Insulin Human Winthropi kasulikkus suhkurtõve ravis on suurem kui sellega kaasnevad riskid.
English: The active substance in Insulin Human Winthrop, insulin human, is produced by a method known as ‘recombinant DNA technology': it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin.
Estonian: Insulin Human Winthropi toimeainet iniminsuliini valmistatakse rekombinant-DNA-tehnika abil: seda toodab bakter, millele on lisatud insuliini teket võimaldav geen (DNA).
English: In the other study, Insulin Human Winthrop Comb 25 was compared with semi-synthetic human insulin.
Estonian: Teises uuringus võrreldi Insuman Winthrop Comb 25 poolsünteetilise iniminsuliiniga.
English: The Insulin Human Winthrop range is comprised of fast-acting insulin solutions (Insulin Human Winthrop Rapid and Insulin Human Winthrop Infusat) that contain soluble insulin, an intermediate-acting insulin suspension (Insulin Human Winthrop Basal) that contains isophane insulin, and combinations of fast- and intermediateacting in various proportions (Insulin Human Winthrop Comb):
Estonian: Ravimisarja Insulin Human Winthropi kuuluvad kiiretoimelise insuliini lahused (Insulin Human Winthrop Rapid ja Insulin Human Winthrop Infusat), mis sisaldavad lahustuvat insuliini; keskmise toimeajaga insuliini suspensioon (Insulin Human Winthrop Basal), mis sisaldab isofaaninsuliini; ning kiiretoimeliste ja keskmise toimeajaga insuliinide eri kombinatsioonid (Insulin Human Winthrop Comb):
English: Insulin Human Winthrop led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin.
Estonian: Insulin Human Winthropi kasutamine vähendas HbA1c sisaldust ning näitas, et organism reguleeris vere glükoosisisaldust samas ulatuses kui muu iniminsuliin.
English: Insulin Human Winthrop can cause hypoglycaemia.
Estonian: Insulin Human Winthrop võib põhjustada hüpoglükeemiat.
English: Insulin Human Winthrop was effective for both type 1 and type 2 diabetes.
Estonian: Insuman Human Winthrop oli tõhus nii I kui ka II tüüpi suhkurtõve korral.
English: Insulin Human Winthrop contains the active substance insulin human.
Estonian: Insulin Human Winthrop sisaldab toimeainena iniminsuliini.
English: The Committee recommended that Insulin Human Winthrop be given marketing authorisation.
Estonian: Komitee soovitas anda Insulin Human Winthropile müügiloa.
English: In one of the studies, Insulin Human Winthrop was used in an insulin pump.
Estonian: Ühes neist uuringutest kasutati Insulin Human Winthropit insuliinipumbas.
English: Insulin Human Winthrop is used in patients with diabetes who need treatment with insulin.
Estonian: Insulin Human Winthropit kasutatakse suhkurtõvega patsientidel, kes vajavad insuliinravi.
English: For the full list of all side effects reported with Insulin Human Winthrop, see the Package Leaflet.
Estonian: Insulin Human Winthropi kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Insulin Human Winthrop Infusat is specially prepared ready to be used in infusion pumps.
Estonian: Insuman Human Winthrop Infusat on spetsiaalne valmislahus kasutamiseks infusioonipumpades.
English: Other information about Insulin Human Winthrop:
Estonian: Muu teave Insulin Human Winthropi kohta
English: Why has Insulin Human Winthrop been approved?
Estonian: Miks Insulin Human Winthrop heaks kiideti?
English: Insulin Human Winthrop is given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor's recommendations.
Estonian: Insulin Human Winthropit manustatakse nahaaluse süstena enamasti kõhueesseina või reide vastavalt arsti soovitustele.
English: What is the risk associated with Insulin Human Winthrop?
Estonian: Mis riskid Insulin Human Winthropiga kaasnevad?
English: See the Package Leaflet for exact timings.
Estonian: Teabe täpse ajastamise kohta leiate pakendi infolehelt.
English: What is Insulin Human Winthrop?
Estonian: Mis on Insulin Human Winthrop?
English: Insulin Human Winthrop is a range of insulin solutions and suspensions for injection.
Estonian: Insulin Human Winthrop on süstitavate insuliinilahuste ja -suspensioonide ravimisari.
English: The full EPAR for Insulin Human Winthrop is available here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Insulin Human Winthropi kohta leiate siit.
English: How has Insulin Human Winthrop been studied?
Estonian: Kuidas Insulin Human Winthropit uuriti?
English: Insulin Human Winthrop is a replacement insulin that is identical to the insulin made by the body.
Estonian: Insuman on asendusinsuliin, mis on identne organismis tekkiva insuliiniga.
English: How does Insulin Human Winthrop work?
Estonian: Kuidas Insulin Human Winthrop toimib?
English: How is Insulin Human Winthrop used?
Estonian: Kuidas Insulin Human Winthropit kasutatakse?
English: What is Insulin Human Winthrop used for?
Estonian: Milleks Insulin Human Winthropit kasutatakse?
English: What benefit has Insulin Human Winthrop shown during the studies?
Estonian: Milles seisneb uuringute põhjal Insulin Human Winthropi kasulikkus?
English: Xeloda received a marketing authorisation valid throughout the EU on 2 February 2001.
Estonian: Xeloda on saanud müügiloa, mis kehtib kogu ELis, 2. veebruaril 2001.
English: The tablets are given twice daily for 14 days followed by a 7-day gap before the next course.
Estonian: Tablette võetakse 2 korda ööpäevas 14 päeva, seejärel tehakse 7-päevane vahepaus enne järgmist ravikuuri.
English: As a result, it prevents the growth of tumour cells and eventually kills them.
Estonian: Selle tulemusena pärsib see kasvajarakkude kasvu ja lõpuks hävitab need.
English: Further information on Xeloda can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Xeloda.
Estonian: Lisateave Xeloda kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Xeloda.
English: What measures are being taken to ensure the safe and effective use of Xeloda?
Estonian: Mis meetmed võetakse, et tagada Xeloda ohutu ja efektiivne kasutamine?
English: Xeloda tablets should be taken within 30 minutes after a meal.
Estonian: Xeloda tabletid tuleb manustada 30 minuti jooksul pärast sööki.
English: The European Medicines Agency therefore decided that Xeloda's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Xeloda kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Xeloda (capecitabine)
Estonian: Xeloda (kapetsitabiin)
English: Xeloda is available as tablets (150 and 500 mg).
Estonian: Xelodat turustatakse tablettidena (150 mg ja 500 mg).
English: Other information about Xeloda
Estonian: Muu teave Xeloda kohta
English: Fluorouracil is very similar to pyrimidine.
Estonian: Fluorouratsiil on väga sarnane pürimidiiniga.
English: Xeloda is taken as tablets, while fluorouracil normally needs to be injected.
Estonian: Xelodat manustatakse tablettidena, samas fluorouratsiili tuleb tavaliselt süstida.
English: For other types of cancer, treatment is stopped if the disease gets worse or the side effects are unacceptable.
Estonian: Ravi peatatakse muude vähiliikide korral, kui haigus süveneb või kui kõrvalnähud on vastuvõetamatud.
English: As for all medicines, data on the use of Xeloda are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Xeloda kasutamise kohta pidevat järelevalvet.
English: • patients who have had severe and unexpected reactions to fluoropyrimidine therapy;
Estonian: • patsiendid, kellel on esinenud raskeid ja ootamatuid reaktsioone fluoropürimidiinravile;
English: What is Xeloda and what is it used for?
Estonian: Mis on Xeloda ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xeloda have been included in the summary of product characteristics and the package leaflet.
Estonian: Xeloda ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Xeloda are carefully evaluated and any necessary action taken to protect patients.
Estonian: Xeloda kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For more information about using Xeloda, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Xeloda kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: • pregnant or breastfeeding women;
Estonian: • rasedad või imetavad patsiendid;
English: Treatment is continued for 6 months after colon surgery.
Estonian: Pärast käärsooleoperatsiooni jätkatakse ravi 6 kuud.
English: The most common side effects with Xeloda are diarrhoea, nausea (feeling sick), vomiting, abdominal (belly) pain, stomatitis (sores in the mouth), palmar-plantar erythrodysaesthesia (hand-foot syndrome, a skin reaction with rash and pain on the hands and feet), tiredness, weakness, loss of appetite, problems due to formation of blood clots in the blood vessels, heart problems and kidney problems in patients who already have reduced kidney function.
Estonian: Xeloda kõige sagedamad kõrvalnähud on kõhulahtisus, iiveldus, oksendamine, kõhuvalu, stomatiit (suuhaavandid), palmaar-plantaarne erütrodüseteesia (sündroom, mille korral tekib nahareaktsioon lööbega kätel ja jalgadel ning valuga nendes), väsimus, nõrkus, isutus, veresoonte trombide tekkega seotud probleemid, südame- ja neeruprobleemid patsientidel, kelle neerutalitus on juba vähenenud.
English: Xeloda contains the active substance capecitabine.
Estonian: Xeloda sisaldab toimeainena kapetsitabiini.
English: Xeloda must also not be used in the following groups:
Estonian: Samuti ei tohi Xelodat kasutada järgmised patsiendirühmad:
English: Xeloda should only be prescribed by a doctor who is experienced in the use of cancer medicines.
Estonian: Xelodat tohib määrata üksnes vähiravimite kasutamises kogenud arst.
English: About two-thirds of the patients taking Xeloda or the combination remained disease-free throughout the 3.8 years of the study.
Estonian: Ligikaudu kaks kolmandikku Xelodat või kombinatsioonravi kasutanud patsientidest olid kogu uuringuperioodil (3,8 aastat) haigusvabad.
English: The safety profile of the medicine is considered acceptable.
Estonian: Xeloda ohutusprofiili peetakse vastuvõetavaks.
English: In the body, fluorouracil takes the place of pyrimidine and interferes with the enzymes involved in making new DNA.
Estonian: Fluorouratsiil asendab organismis pürimidiini ja häirib uue DNA sünteesis osalevaid ensüüme.
English: • patients taking brivudine (an antiviral medicine for treating shingles or chickenpox) or who have taken it in the last 4 weeks.
Estonian: • patsiendid, kes kasutavad brivudiini (viirusvastane ravim vöötohatise või tuulerõugete raviks) või kes on kasutanud seda eelneval 4 nädalal.
English: Xeloda has been shown to be effective in treating colon, colorectal, gastric and breast cancer.
Estonian: Xeloda on osutunud efektiivseks käärsoole-, kolorektaal-, mao- ja rinnavähi ravis.
English: The disease responded in 19 to 25% of patients treated with Xeloda, compared with 12 to 15% with the comparator combination.
Estonian: Xelodaga ravitute seas oli patsiente, kellel haigus reageeris ravile, 19-25% ning võrdlusravimi rühmas 12-15%.
English: Two smaller studies (238 patients) showed that Xeloda was effective after treatment with taxanes and anthracyclines did not work.
Estonian: Kahes väiksemas uuringus (238 patsienti) tõendati, et Xeloda oli efektiivne pärast seda, kui ravi taksaanide ja antratsükliinidega ei andnud tulemusi.
English: What are the risks associated with Xeloda?
Estonian: Mis riskid Xelodaga kaasnevad?
English: • locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body).
Estonian: • lokaalne kaugelearenenud või metastaatiline rinnavähk (rinnavähk, mis on hakanud levima organismis ka mujale).
English: Doses need to be adjusted for patients with liver or kidney disease and for patients who develop certain side effects.
Estonian: Annuseid on vaja kohandada maksa- või neeruhaigusega patsientidel ja teatud kõrvalnähtude tekkimisel.
English: For the full list of side effects reported with Xeloda, see the package leaflet.
Estonian: Xeloda kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Xeloda must not be used in people who may be hypersensitive (allergic) to capecitabine, to any of the other ingredients, or to fluorouracil.
Estonian: Xelodat ei tohi kasutada patsiendid, kes võivad olla kapetsitabiini, selle ravimi mis tahes muu koostisaine või fluorouratsiili suhtes ülitundlikud (allergilised).
English: Results showed that when either Xeloda or fluorouracil and folinic acid were used with oxaliplatin, it took an average of 8 months for the disease to get worse in patients who had not been treated before, and 5 months in patients whose previous treatment had not worked.
Estonian: Tulemuste põhjal kulus Xeloda või fluorouratsiili ja foliinhappe kasutamisel koos oksaliplatiiniga varem ravimata patsientidel haiguse süvenemiseni keskmiselt 8 kuud ja varem tulemusteta ravitud patsientidel 5 kuud.
English: How is Xeloda used?
Estonian: Kuidas Xelodat kasutatakse?
English: Xeloda is used on its own or with other cancer medicines;
Estonian: Xelodat kasutatakse ainuravimina või koos muude vähiravimitega;
English: • patients with complete absence of activity of the dihydropyrimidine dehydrogenase enzyme;
Estonian: • dihüdropürimidiindehüdrogenaasi (teatud ensüümi) täieliku vaegusega patsiendid;
English: The dose depends on the patient's height and weight and the type of cancer being treated.
Estonian: Annus sõltub patsiendi kasvust ja kehamassist ning ravitavast vähiliigist.
English: Patients taking Xeloda with docetaxel had a longer time before the disease got worse compared with patients taking docetaxel on its own (186 days compared with 128 days).
Estonian: Xelodat koos dotsetakseeliga kasutanud patsientidel tekkis haiguse süvenemine hiljem kui dotsetakseeli ainuravimina kasutanud patsientidel (vastavalt 186 päeva ja 128 päeva).